BioMed X and Merck extend research collaboration

The two entered a partnership in 2013 and the resulting research has led to 25 scientific publications

BioMed X has announced the extension of an ongoing collaboration with Merck. Under the agreement, Merck will start up to six additional research projects at the BioMed X Institute, building on ongoing projects in oncology and autoimmunity. The next joint global crowdsourcing project will explore mechanisms of immune senescence and mitochondrial dysfunction in regulatory T cells and other T cell subsets that are shared in human autoimmunity and ageing.

Merck entered a partnership with BioMed X in 2013. Since then, the partnership has steadily grown and previously initiated research projects led to 25 scientific publications on topics such as in silico design of selective kinase inhibitors, myeloid-derived suppressor cell activity, Golgi stress, and DNA damage, as well as several potential drug target genes which have been further investigated in pre-clinical studies at Merck.

“We are very grateful for the trust and support we received from Merck over the past eight years since we started our collaboration,” Christian Tidona, founder and MD of the BioMed X Institute said. “This new agreement with Merck is a great validation of our unique innovation model, showing that it delivers sustained translational value to the early R&D pipelines of our pharma partners.”

“We are excited to strengthen our ongoing commitment to our partnership with BioMed X,” said Ulrich A.K. Betz, VP Innovation at Merck. “As a result of this successful collaboration, multiple innovative discovery projects in new research areas have been started at Merck, including the successful implementation of our open innovation concept ‘outcubation’ published in Nature Biotechnology, and we look forward to the scientific advances to come.”

The new research projects will build on this ongoing work, as well as BioMed X’s expertise in the fields of immunology and inflammation and Merck’s in-house discovery capabilities in oncology, immuno-oncology and immunology.

Companies